Search
A new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.
New research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.
The Kids Research Institute Australia researchers have been awarded 12 of 16 grants under the latest round of funding from the WA Child Research Fund
Cancer research is being reimagined after a collaboration between The Kids Research Institute Australia, the Peter Doherty Institute for Infection and Immunity.
A team of Australian scientists including cancer researchers from The Kids Research Institute Australia have made a crucial breakthrough in understanding how the immune system puts cancer to sleep.
Baxter Hutchinson was diagnosed with two life-threatening brain tumours a year ago, aged 17. Since then he has undergone surgery, radiotherapy and chemotherapy in his journey to beat the cancer.
The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.
Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as a result of therapy. It is evident that there is a need for safer, more effective treatments for pediatric EPN patients.
This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years.
Components of the bone marrow microenvironment (BMM) have been shown to mediate the way in which leukemia develops, progresses and responds to treatment. Increasing evidence shows that leukemic cells hijack the BMM, altering its functioning and establishing leukemia-supportive interactions with stromal and immune cells.